In a move aimed at fundamentally restructuring the operational landscape of radiation oncology, Fuse Oncology has entered into a strategic collaboration with Associated Medical Professionals of New York (AMP). The partnership marks the official launch of a high-stakes proof-of-concept trial for the "FuseRx" clinical workflow platform, an innovative software suite designed to unify the disjointed administrative and clinical silos that frequently impede timely cancer treatment.
The trial is currently underway at AMP’s Center of Advanced Radiation Excellence in Syracuse, New York. As an affiliate of the private equity-backed US Urology Partners, AMP serves as the ideal testing ground for a technology platform that promises to transition prostate cancer care from fragmented, multi-system management to a cohesive, single-plan operation.
The Core Challenge: Operational Fragmentation in Oncology
The current standard of care for prostate cancer often involves a complex web of hand-offs between various specialists, including urologists, radiation oncologists, physicists, dosimetrists, and nursing staff. Traditionally, these stakeholders rely on disparate electronic medical record (EMR) systems and oncology information systems that do not always communicate seamlessly. This fragmentation often leads to administrative bottlenecks, redundant data entry, and, most critically, delays in the transition from initial diagnosis to the delivery of radiation therapy.
FuseRx is engineered to sit alongside these existing legacy systems, acting as an orchestration layer. Its primary goal is to consolidate the entire patient journey—from the initial consultation and treatment planning to the final delivery of therapy—into a single, unified workflow.
Chronology: Building Toward a Unified Workflow
The collaboration between Fuse Oncology and AMP is the culmination of several years of strategic development in the digital health space:
- March 2025: Fuse Oncology achieves a major milestone by securing an agreement with the American College of Radiation Oncology (ACRO) to integrate standardized clinical pathways directly into the FuseRx software. This integration ensures that the software does not just track tasks, but enforces evidence-based, high-quality clinical decision-making.
- Late 2025 – Early 2026: Development teams focus on the interoperability of FuseRx with existing EMR infrastructures, ensuring that the platform can "plug and play" without requiring a wholesale replacement of the clinic’s expensive legacy software.
- September 2026: The formal proof-of-concept trial launches at the Center of Advanced Radiation Excellence in Syracuse. The initial phase focuses on physician consultation workflows, the formalization of treatment intent, and the live implementation of ACRO’s clinical pathways.
- Future Outlook (Q4 2026 and Beyond): The collaboration intends to layer in additional operational roles, including physics-based planning and nursing coordination, to complete the end-to-end integration of the radiation oncology department.
Technical Scope: How FuseRx Functions
The FuseRx platform functions as a "single source of truth." In the current clinical environment, a physician may enter data into an EMR, while a dosimetrist works in a separate treatment planning system, and a scheduler manages appointments in a third, often disconnected, software.
By unifying these functions, FuseRx allows:
- Integrated Clinical Pathways: By embedding ACRO pathways, the system prompts providers to adhere to best practices in real-time, reducing variability in care.
- Administrative Consolidation: Automated triggers ensure that as soon as a treatment intent is signed off, the necessary administrative and insurance-related paperwork is generated, bypassing the "lag time" that often plagues busy practices.
- Real-Time Collaboration: Because the platform is designed to be viewed by the entire multidisciplinary team, communication errors regarding treatment doses or patient scheduling are significantly minimized.
Official Perspectives: The Synergy of Urology and Oncology
The leadership behind this project emphasizes that the choice of AMP as the primary testing site was intentional.
Dr. Steven Finkelstein, the Director of Radiation Oncology Research at AMP and the National Director of the Center of Advanced Radiation Excellence, notes that the urology setting provides a unique vantage point.
"A urology practice sees prostate cancer from the first PSA test to the last follow-up appointment," Dr. Finkelstein explained. "When radiation is the right clinical answer, the patient shouldn’t have to wait while paperwork moves between siloed systems. We are testing whether a singular, unified workflow—with ACRO’s clinical pathways baked into the core—gets our patients from consultation to treatment faster and more consistently. Syracuse is where we find out."

James Bauler, CEO of Fuse Oncology, echoed these sentiments, highlighting the "one team, one roof" philosophy that defines modern independent urology.
"Independent urology is where a significant volume of prostate cancer radiation happens, and it is a setting built for speed," Bauler stated. "It is the perfect environment to stress-test an end-to-end workflow for radiation oncology. Dr. Finkelstein and the AMP team are the ideal partners to demonstrate that software should facilitate care, not complicate it."
Implications for the Future of Cancer Care
The success of this proof-of-concept trial could have far-reaching implications for the oncology sector, particularly as independent practices face increasing pressure to demonstrate high-quality outcomes while maintaining operational efficiency.
1. The Rise of "Software-Defined" Clinical Pathways
By automating the adherence to ACRO clinical pathways, FuseRx effectively turns clinical guidelines into active digital guardrails. This reduces the risk of "guideline drift," where providers might deviate from established standards due to time pressure or lack of immediate access to current protocols.
2. Impact on Patient Experience
For the patient, the primary benefit is the reduction of "dead time." In cancer care, the interval between diagnosis and the commencement of treatment is often a period of extreme anxiety. By streamlining the administrative backend, FuseRx aims to compress this timeline, allowing for earlier intervention and a more seamless experience for patients navigating a difficult diagnosis.
3. Economic and Operational Efficiency
Operational fragmentation is not only a clinical issue but a financial one. Managing manual hand-offs between departments requires significant administrative labor. If FuseRx proves that it can automate these processes, it could provide a template for independent practices to remain competitive against larger, hospital-based systems that often have the resources to build proprietary, unified software stacks.
4. Setting a New Standard for Interoperability
Perhaps the most significant long-term implication is the proof that third-party, specialized software can successfully "wrap" around existing EMRs. If the Syracuse trial demonstrates that FuseRx can coexist with major EMR systems without data loss or security vulnerabilities, it could open the door for a wave of modular software solutions that allow specialty clinics to customize their digital infrastructure without abandoning their core medical records.
Conclusion: A Benchmark for Success
The coming months in Syracuse will be closely watched by industry analysts, medical technology developers, and oncology networks across the United States. As the project expands from physician consultations to the more complex domains of radiation physics and therapeutic delivery, the data collected will provide the first robust look at whether "one workflow" can truly redefine the speed and quality of prostate cancer care.
If the FuseRx platform successfully navigates the complexities of the AMP environment, it will represent a milestone in digital health—a transition from passive medical records to active, intelligent clinical orchestration. For patients under the care of AMP, the promise is clear: less time spent waiting for systems to talk to each other, and more time focused on the only thing that matters—the treatment and recovery process.
